Efficacy evaluation through human trials is crucial for advancing a vaccine candidate to
clinics. Next-generation sequencing (NGS) can be used to quantify B cell repertoire …

Background The first commercialized hepatitis E vaccine, HEV 239, has been shown to be
safe and highly immunogenic, the protection as well as the vaccine-induced anti-HEV …

Highlights•Hepatitis E vaccine derived from E. coli proved to be a successful B-cell
vaccine.•Antigenicity and immunogenicity are prerequisite considerations in vaccine …

Objective Naturally acquired anti–hepatitis E virus (HEV) immunity can protect against new
HEV infections. The aim of this study was to analyse the persistence of naturally acquired …

Abstract Background Hepatitis E virus (HEV) is of global significance. HEV is a common
cause of acute hepatitis in China. One of the major unanswered questions about HEV is the …

Background This study aimed to evaluate the safety and tolerability for variable dosages of a
novel hepatitis E vaccine p179. Methods The randomized open-label parallel control phase …

China's Ministry of Science and Technology approved the first vaccine against the hepatitis
E virus (HEV). The HEV 239 vaccine developed and manufactured by Xiamen Innovax …

Hepatitis E virus (HEV) infection is a major cause of acute hepatitis but also provokes
chronic infection in immunocompromised patients. Although the pathogenesis and treatment …

Background Hepatitis E virus (HEV) is a leading cause of acute hepatitis. The long-term
efficacy of a hepatitis E vaccine needs to be determined. Methods In an initial efficacy study …

Hepatitis E virus (HEV) infection causes sporadic outbreaks of acute hepatitis worldwide.
HEV was previously considered to be restricted to resource-limited countries with poor …